Original Article

You have full text access to this OnlineOpen article

Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia†

  1. William G. Wierda MD, PhD1,
  2. Thomas J. Kipps MD, PhD2,
  3. Michael J. Keating MB, BS1,
  4. Jennifer R. Brown MD, PhD3,
  5. John G. Gribben MD, PhD4,
  6. Mary Browning RN5,
  7. Laura Z. Rassenti PhD2,
  8. Andrew W. Greaves BS2,
  9. Donna Neuberg ScD6,
  10. Susan M. O'Brien MD1,‡,*,
  11. and the CLL Research Consortium

Article first published online: 30 AUG 2010

DOI: 10.1002/cncr.25379

Issue

Cancer

Cancer

Volume 117, Issue 1, pages 116–124, 1 January 2011

Additional Information

How to Cite

Wierda, W. G., Kipps, T. J., Keating, M. J., Brown, J. R., Gribben, J. G., Browning, M., Rassenti, L. Z., Greaves, A. W., Neuberg, D., O'Brien, S. M. and and the CLL Research Consortium (2011), Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer, 117: 116–124. doi: 10.1002/cncr.25379

Author Information

  1. 1

    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Hematology/Oncology, Moores University of California-San Diego Cancer Center, University of California, San Diego, California

  3. 3

    Department of Medical Oncology/Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts

  4. 4

    Department of Haematology, Center for Medical Oncology, Barts and The London School of Medicine, London, United Kingdom

  5. 5

    Genzyme Oncology, Cambridge, Massachusetts

  6. 6

    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts

  1. ‡

    Fax: (713) 794-4297

*Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030

  1. †

    W. G. Wierda performed research, analyzed data, and wrote the article; T. J. Kipps, M. J. Keating, J. R. Brown, and J. G. Gribben performed research; M. Browning, L. Z. Rassenti, and A. W. Greaves collected data; D. Neuberg analyzed data; and S. M. O'Brien designed the study, performed research, analyzed data, and wrote the article.

  2. ‡

    Fax: (713) 794-4297

Publication History

  1. Issue published online: 16 DEC 2010
  2. Article first published online: 30 AUG 2010
  3. Manuscript Accepted: 11 FEB 2010
  4. Manuscript Revised: 11 JAN 2010
  5. Manuscript Received: 12 JUL 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (264K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Fie Juhl Vojdeman, Jesper Jurlander, Mars van't Veer, Maija Itälä-Remes, Eva Kimby, Geir Erland Tjønnfjord, Jan Walewski, Tomas Kozák, Aaron Polliack, Michela Montagna, Mario Regazzi, Nikolai Kirkby, Marinus van Oers, Christian Hartmann Geisler, Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis, Leukemia & Lymphoma, 2013, 54, 4, 790

    CrossRef

  2. 2
    L. Sellner, S. Denzinger, S. Dietrich, H. Glimm, O. Merkel, P. Dreger, T. Zenz, What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion?, Current Hematologic Malignancy Reports, 2013, 8, 1, 81

    CrossRef

  3. 3
    David Oscier, Claire Dearden, Efrem Eren, Christopher Fegan, George Follows, Peter Hillmen, Tim Illidge, Estella Matutes, Don W. Milligan, Andrew Pettitt, Anna Schuh, Jennifer Wimperis, Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia, British Journal of Haematology, 2012, 159, 5
    Direct Link:
  4. 4
    Eric van den Neste, Rémi Letestu, Thérèse Aurran-Schleinitz, Loïc Ysebaert, Pierre Feugier, Stéphane Leprêtre, Caroline Dartigeas, Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?, Leukemia & Lymphoma, 2012, 53, 3, 362

    CrossRef

  5. 5
    Mark J. Adler, Dimiter S. Dimitrov, Therapeutic Antibodies Against Cancer, Hematology/Oncology Clinics of North America, 2012, 26, 3, 447

    CrossRef

  6. 6
    Nicole Skoetz, Kathrin Bauer, Thomas Elter, Ina Monsef, Verena Roloff, Michael Hallek, Andreas Engert, Alemtuzumab for patients with chronic lymphocytic leukaemia, The Cochrane Library,
    Direct Link:
View Full Article (HTML) Get PDF (264K)